Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB)
Introduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed 6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance threatens the global effort to eradicate this disease. With limited options available, add...
Saved in:
Main Authors: | Lee, Bei Shi, Pethe, Kevin |
---|---|
Other Authors: | School of Biological Sciences |
Format: | Article |
Language: | English |
Published: |
2022
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/155760 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis
by: Lee, Bei Shi, et al.
Published: (2022) -
Cryo-electron microscopy structure of the Mycobacterium tuberculosis cytochrome bcc:aa₃ supercomplex and a novel inhibitor targeting subunit cytochrome cI
by: Mathiyazakan, Vikneswaran, et al.
Published: (2023) -
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis
by: Lee, Bei Shi, et al.
Published: (2021) -
Naturally-occurring polymorphisms in QcrB are responsible for resistance to Telacebec in Mycobacterium abscessus
by: Sorayah, Ria, et al.
Published: (2021) -
GaMF1.39’s antibiotic efficacy and its enhanced antitubercular activity in combination with Clofazimine, Telacebec, ND-011992 or TBAJ-876
by: Ragunathan, Priya, et al.
Published: (2023)